COPENHAGEN, Denmark, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Zealand informs that new preclinical data on its novel GIP receptor agonist, ZP-I-98, will be presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting, taking place on 14th - 18th September, 2015 in Stockholm, Sweden. ZP-I-98 is invented and wholly-owned by Zealand.
ZP-I-98 - A novel long-acting GIP receptor agonist
One investigational approach to enhance the efficacy of GLP-1 receptor agonists, used for the management of Type 2 diabetes, includes combination therapy with a glucose-dependent insulinotropic peptide (GIP) receptor agonist. Recent preclinical studies conducted by Zealand with its novel GIP receptor agonist, ZP-1-98, have shown that a GIP/GLP-1 combination therapy could enhance the treatment of Type 2 diabetes by inducing both robust glycemic control as well as a greater loss of body weight than seen by a single treatment. ZP-1-98 has a long-acting profile, which indicates that it could be suitable for convenient once-weekly dosing.